Long-Term Extension Study of Ritlecitinib in Severe Alopecia Areata

• Ritlecitinib higher dose

  Participants receive 1 ritlecitinib higher dose capsule QD and 1 placebo lower dose capsule QD orally for up to 3 years.

• Ritlecitinib lower dose

  Participants receive 1 ritlecitinib lower dose capsule QD and 1 placebo higher dose capsule QD orally for up to 3 years.

Primary

• Incidence of treatment-emergent adverse eventsup to 3 years

• Incidence of Serious Adverse Events and AEs leading to permanent discontinuationup to 3 years

Secondary

• Proportion of participants achieving absolute Severity of Alopecia Tool score ≤1036 months

• Proportion of participants achieving absolute Severity of Alopecia Tool score ≤2036 months

• Change from baseline in Severity of Alopecia Tool score36 months

• Proportion of participants achieving at least 2 grade improvement or a score of 3 in eyebrow assessment36 months

• Proportion of participants achieving at least 2 grade improvement or a score of 3 in eyelash assessment36 months

• Proportion of participants achieving Patient Global Impression of Change response36 months

• Change from baseline in PROMIS Parent Proxy Anxiety Symptoms T-score36 months

• Change from baseline in Behavior Rating Inventory of Executive Function T-scores36 months